{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:20Z","timestamp":1785024020617,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Center MS and Autoimmune Neurology, Mayo Clinic","award":["for publication costs"],"award-info":[{"award-number":["for publication costs"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"DOI":"10.1007\/s00401-026-03053-y","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T23:02:13Z","timestamp":1785020533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aquaporin-4\u2019s dynamic expression and biological variations within the tumor obscure the paraneoplastic phenomenon in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder"],"prefix":"10.1007","volume":"152","author":[{"given":"Naga Pradyumna","family":"Kothapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisa","family":"Vorasoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M.","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanthaya","family":"Tisavipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando X.","family":"Cuascut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemali Y.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia F.","family":"Lucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"3053_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocn.2017.10.030","volume":"48","author":"\u00c1 Annus","year":"2018","unstructured":"Annus \u00c1, Bencsik K, Ob\u00e1l I, Kincses ZT, Tiszlavicz L, H\u00f6ftberger R et al (2018) Paraneoplastic neuromyelitis optica spectrum disorder: a case report and review of the literature. J Clin Neurosci Off J Neurosurg Soc Australas 48:7\u201310. https:\/\/doi.org\/10.1016\/j.jocn.2017.10.030","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"issue":"12","key":"3053_CR2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3390\/cancers11121","volume":"11","author":"E Aric\u00f2","year":"2019","unstructured":"Aric\u00f2 E, Castiello L, Capone I, Gabriele L, Belardelli F (2019) Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers (Basel) 11(12):1943. https:\/\/doi.org\/10.3390\/cancers11121 (Published 2019 Dec 4)","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3053_CR3","doi-asserted-by":"publisher","first-page":"111226","DOI":"10.1016\/j.humimm.2024.111226","volume":"86","author":"D Cheung","year":"2025","unstructured":"Cheung D, Hassan MA, Huynh T, Feng X, Wang H (2025) Shedding light on the role of complement C4 activation in cancer. Hum Immunol 86(1):111226. https:\/\/doi.org\/10.1016\/j.humimm.2024.111226","journal-title":"Hum Immunol"},{"issue":"2","key":"3053_CR4","doi-asserted-by":"publisher","first-page":"BSR20180108","DOI":"10.1042\/BSR20180108","volume":"38","author":"M Chetry","year":"2018","unstructured":"Chetry M, Li S, Liu H, Hu X, Zhu X (2018) Prognostic values of aquaporins mRNA expression in human ovarian cancer. Biosci Rep 38(2):BSR20180108. https:\/\/doi.org\/10.1042\/BSR20180108","journal-title":"Biosci Rep"},{"issue":"4","key":"3053_CR5","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JG, Desestret V, Dubey D et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8(4):e1014. https:\/\/doi.org\/10.1212\/NXI.0000000000001014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"3053_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/brain\/awab394","volume":"145","author":"Y Guo","year":"2022","unstructured":"Guo Y, Lennon VA, Parisi JE, Popescu B, Vasquez C, Pittock SJ et al (2022) Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain J Neurol 145(4):1379\u20131390. https:\/\/doi.org\/10.1093\/brain\/awab394","journal-title":"Brain J Neurol"},{"issue":"19","key":"3053_CR7","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.3390\/jcm11195954","volume":"11","author":"L Jasckiewicz","year":"2022","unstructured":"Jasckiewicz L, Hejne K, Szostak B, Osowiecka K, Skowronski MT, Lepiarczyk E et al (2022) Expression profiles of AQP3 and AQP4 in lung adenocarcinoma samples generated via bronchoscopic biopsies. J Clin Med 11(19):5954. https:\/\/doi.org\/10.3390\/jcm11195954","journal-title":"J Clin Med"},{"issue":"9","key":"3053_CR8","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari N, Dwarakanath BS, Das A, Bhatt AN (2016) Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol J Int Soc Oncodev Biol Med 37(9):11553\u201311572. https:\/\/doi.org\/10.1007\/s13277-016-5098-7","journal-title":"Tumor Biol J Int Soc Oncodev Biol Med"},{"issue":"12","key":"3053_CR9","doi-asserted-by":"publisher","first-page":"e25078","DOI":"10.1097\/MD.0000000000025078","volume":"100","author":"L Liu","year":"2021","unstructured":"Liu L, Sun X, Yuan C, Liu H (2021) Relationship between HLA-DRB1 gene polymorphism and breast cancer: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 100(12):e25078. https:\/\/doi.org\/10.1097\/MD.0000000000025078","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3053_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ana.26722","volume":"94","author":"M Majed","year":"2023","unstructured":"Majed M, Valencia Sanchez C, Bennett JL, Fryer J, Mulligan MD, Redenbaugh V et al (2023) Alterations in aquaporin-4-IgG serostatus in 986 patients: a laboratory-based longitudinal analysis. Ann Neurol 94(4):727\u2013735. https:\/\/doi.org\/10.1002\/ana.26722","journal-title":"Ann Neurol"},{"issue":"7","key":"3053_CR11","doi-asserted-by":"publisher","first-page":"e40770","DOI":"10.1371\/journal.pone.0040770","volume":"7","author":"D Niu","year":"2012","unstructured":"Niu D, Kondo T, Nakazawa T, Kawasaki T, Yamane T, Mochizuki K et al (2012) Differential expression of aquaporins and its diagnostic utility in thyroid cancer. PLoS ONE 7(7):e40770. https:\/\/doi.org\/10.1371\/journal.pone.0040770","journal-title":"PLoS ONE"},{"issue":"2","key":"3053_CR12","doi-asserted-by":"publisher","first-page":"e200548","DOI":"10.1212\/NXI.0000000000200548","volume":"13","author":"PS Rommer","year":"2026","unstructured":"Rommer PS, Jiang W, Nolte JP, Mikami T, De Seze J, S\u00e1nchez P et al (2026) Complement inhibition for acute neuromyelitis optica spectrum disorder attacks: insights from an international case series. Neurol Neuroimmunol Neuroinflamm 13(2):e200548. https:\/\/doi.org\/10.1212\/NXI.0000000000200548","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"3053_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jso.22155","volume":"106","author":"Z Shi","year":"2012","unstructured":"Shi Z, Zhang T, Luo L, Zhao H, Cheng J, Xiang J et al (2012) Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. J Surg Oncol 106(3):267\u2013272. https:\/\/doi.org\/10.1002\/jso.22155","journal-title":"J Surg Oncol"},{"key":"3053_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2407-11-161","volume":"11","author":"A Warth","year":"2011","unstructured":"Warth A, Muley T, Meister M, Herpel E, Pathil A, Hoffmann H et al (2011) Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer 11:161. https:\/\/doi.org\/10.1186\/1471-2407-11-161","journal-title":"BMC Cancer"},{"key":"3053_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nri2742","volume":"10","author":"W Zou","year":"2010","unstructured":"Zou W, Restifo N (2010) TH17 cells in tumor immunity and immunotherapy. Nat Rev Immunol 10:248\u2013256. https:\/\/doi.org\/10.1038\/nri2742","journal-title":"Nat Rev Immunol"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-026-03053-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-026-03053-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-026-03053-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T23:02:13Z","timestamp":1785020533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-026-03053-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1007\/s00401-026-03053-y","relation":{},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Naga Pradyumna Kothapalli has no disclosures or conflicts of interest. Yong Guo has no disclosures or conflicts of interest. Nisa Vorasoot has no disclosures or conflicts of interest. Dean M Wingerchuk reports personal fees for consulting or advisory board participation from Biogen, Genentech, Horizon Pharmaceuticals, MedImmune, Mitsubishi Tanabe, Novartis, Reistone Biopharma, Bristol Myers Squibb, Imcyse, Merck Serono, Roche Pharmaceuticals, TTY Biopharm, Viela Bio, UCB Pharma, and Alexion; research support paid to the Mayo Clinic by Alexion; and payment for service on clinical trial adjudication committees for MedImmune, Viela Bio, and UCB Pharma. Dr Flanagan has served on Alexion, Genentech, Horizon Therapeutics and UCB advisory boards. He has received research support from UCB. He received royalties from UpToDate. Dr Flanagan is a site principal investigator in a randomized clinical trial of Rozanolixizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by UCB. Dr Flanagan is a site principal investigator and a member of the steering committee for a clinical trial of satralizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by Roche\/Genentech. Dr Flanagan is a Co-Investigator on a study of ravulizumab for neuromyelitis optica spectrum disorder run by Alexion. Dr Flanagan has given educational talks on neuromyelitis optica spectrum disorder funded by Alexion. Dr Flanagan has received funding from the NIH (R01NS113828). Dr Flanagan has received honoraria for editing and writing articles for The Continuum Lifelong Learning in Neurology Journal which is a publication of the American Academy of Neurology. Dr Flanagan is a member of the medical advisory board of the MOG project and Sumaira Foundation. Dr Flanagan is an editorial board member of Neurology, Neuroimmunology and Neuroinflammation, The Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. Divyanshu Dubey has consulted for UCB, Immunovant, Argenx, Arialys, and Astellas Pharmaceuticals. All compensation for consulting activities is paid directly to the Mayo Clinic. He has patents pending for KLHL11, LUZP4-IgG, and cavin-4-IgG as markers of neurological autoimmunity. Dr. Dubey has received funding from the DOD (CA210208, PR220430), David J. Tomassoni\u2019s ALS Research Grant, and UCB. Nanthaya Tisavipat has no disclosures or conflicts of interest. Fernando X. Cuascut has participated in EMD Serono, Genentech, Novartis, Amgen, and TG Therapeutics boards. Hemali Patel has no disclosures or conflicts of interest. Claudia F Lucchinetti has no disclosures or conflicts of interest. Sean J. Pittock has grants, personal fees, and non-financial support from Alexion Pharmaceuticals; grants, personal fees, and non-financial support from MedImmune\/Viela Bio; and personal fees for consulting from Genentech, Roche, UCB, and Astellas. He has two patents issued (8889102; application 12-678350; Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia; and 9891219B2; application 12-573942; methods for Treating Neuromyelitis Optica [NMO] by Administration of Eculizumab to an individual that is Aquaporin-4 [AQP4]-IgG Autoantibody positive). Sean J. Pittock also has patents pending for IgGs to the following proteins as biomarkers of autoimmune neurological disorders: septin-5, Kelch-like protein 11, GFAP, PDE10A, and MAP1B.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"11"}}